StemCell Therapy

First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial

Data to be presented today in an oral presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS)

BUFFALO, N.Y., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced results from a pivotal Phase III clinical trial showed oral paclitaxel and encequidar had superior response and survival with much lower incidence and severity of neuropathy compared to IV paclitaxel in the treatment of metastatic breast cancer. For additional details on the study results, please refer to the abstract GS6-01, which can be found online here.

Dr. Rudolf Kwan, Chief Medical Officer of Athenex, commented, Oral paclitaxel and encequidar is the first oral taxane to demonstrate in a Phase III study statistically significant improvement in response rate and median overall survival compared to IV paclitaxel, in the treatment of metastatic breast cancer while associated with a much lower incidence and severity of neuropathy. We believe these data suggest the potential for oral paclitaxel and encequidar to provide an important advance in the management of patients with metastatic breast cancer.

These results will be presented in an oral presentation today at the 2019 San Antonio Breast Cancer Symposium (SABCS) at 3:15 p.m. CT in General Session 6 in Hall 3 of the Henry B. Gonzalez Convention Center in San Antonio, Texas, and were selected for the official SABCS press program at 7:30 a.m. CT.

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next-generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Companys current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on nonabsorbed P-glycoprotein inhibition, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) arginine deprivation therapy. Athenexs employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit http://www.athenex.com.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as anticipate, believe, continue, could, estimate, evaluate, expect, foresee, guidance, intend, investigate, likely, may, plan, potential, predict, preliminary, prepare, potential, probable, project, promising, seek, should, will, would, and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third partiesfor success in certain areas of Athenexs business; our history of operating losses and need to raise additional capital to continue as a going concern; our ability to integrate CIDALs assets into our existing operations; competition; intellectual property risks; risks relating to doing business inChina; the uncertainty of when, if at all, we will be able to resume producing API in ourChongqingplant; and the other risk factors set forth from time to time in ourSECfilings, copies of which are available for free in the Investor Relations section of our website athttp://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-secor upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

CONTACTSAthenex, Inc.:Jacqueline LiCorporate Development and Investor RelationsEmail: JacquelineLi@athenex.com

Investor Relations:Tim McCarthyManaging Director, LifeSci Advisors, LLCDirect: 212-915-2564

See the original post here:

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic...

A profound analysis of the industry based on the "Chemotherapy Induced Peripheral Neuropathy Treatment Market" all over the world is named as Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Report. The research report assesses the current as well as the upcoming performance of the Chemotherapy Induced Peripheral Neuropathy Treatment market, in addition to with newest trends in the market. The major player of the Chemotherapy Induced Peripheral Neuropathy Treatment market (Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma)are also included in the market report. The report forecasts the future of the Chemotherapy Induced Peripheral Neuropathy Treatment market on the basis of this evaluation.

The research analysis for Chemotherapy Induced Peripheral Neuropathy Treatment market comprises each and every feature of the market all over the world, which starts from the Chemotherapy Induced Peripheral Neuropathy Treatment market description and ends on the Chemotherapy Induced Peripheral Neuropathy Treatment market segmentation (Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others). In addition to this, each section of the Chemotherapy Induced Peripheral Neuropathy Treatment market is categorized and evaluated on the basis of goods, the end-user clients of the Chemotherapy Induced Peripheral Neuropathy Treatment market, and the employment of the products. The geographical categorization of the Chemotherapy Induced Peripheral Neuropathy Treatment market (Platinum Agents, Taxanes, Vinca Alkaloids, Others) has also been evaluated thoroughly in the report.

Ask for sample link here: https://www.intenseresearch.com/market-analysis/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2019.html#request-sample

The Chemotherapy Induced Peripheral Neuropathy Treatment perusers will discover this report exceptionally advantageous in the comprehension of the Chemotherapy Induced Peripheral Neuropathy Treatment showcase in the nitty-gritty. The angles and data are spoken to in the Chemotherapy Induced Peripheral Neuropathy Treatment report utilizing figures, structured presentations, pie graphs, and other visual portrayals. This escalates the Chemotherapy Induced Peripheral Neuropathy Treatment pictorial portrayal and furthermore helps in getting the Chemotherapy Induced Peripheral Neuropathy Treatment business actualities much better. The Chemotherapy Induced Peripheral Neuropathy Treatment advertise is probably going to develop at a noteworthy CAGR. The principle goal of the Chemotherapy Induced Peripheral Neuropathy Treatment report is to direct the client to comprehend the Chemotherapy Induced Peripheral Neuropathy Treatment advertise as far as its definition, order, Chemotherapy Induced Peripheral Neuropathy Treatment showcase potential, most recent patterns, and the difficulties that the Chemotherapy Induced Peripheral Neuropathy Treatment advertises is confronting.

Questions replied in this Chemotherapy Induced Peripheral Neuropathy Treatment report: https://www.intenseresearch.com/market-analysis/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2019.html

1. What will the Chemotherapy Induced Peripheral Neuropathy Treatment advertise projection and what will the advancement rate by 2024?

2. What are the major Chemotherapy Induced Peripheral Neuropathy Treatment advertise designs?

3. What is the development of driving components of the Chemotherapy Induced Peripheral Neuropathy Treatment industry?

4. What are the snags being developed to the Chemotherapy Induced Peripheral Neuropathy Treatment showcase?

5. Who are the Chemotherapy Induced Peripheral Neuropathy Treatment driving sellers in a market?

6. What are the market space and limitations by the Chemotherapy Induced Peripheral Neuropathy Treatment key sellers?

7. What are the Chemotherapy Induced Peripheral Neuropathy Treatment driving sellers quality through SWOT and PESTEL consider?

Another area of the Chemotherapy Induced Peripheral Neuropathy Treatment advertise report uncovers the procedure of creation. Be that as it may, this procedure gauges nitty-gritty Chemotherapy Induced Peripheral Neuropathy Treatment think about with respect to assembling cost which incorporates crude stock, and diverse providers for modern offices.

Enquire about our report with our industry authority:

Overall Chemotherapy Induced Peripheral Neuropathy Treatment Market Report Importance:

Our report significantly fixates around genuine research on each part and its general result on the Chemotherapy Induced Peripheral Neuropathy Treatment showcase advance.

The objective gathering of watchers of the Chemotherapy Induced Peripheral Neuropathy Treatment report acclimatizes new wannabes planning to wind up an expansive comprehension of the business, masters, monetary establishments, real accomplices, profitability, Chemotherapy Induced Peripheral Neuropathy Treatment wholesalers, and industry organization.

To get the examination techniques those are being gathered by Chemotherapy Induced Peripheral Neuropathy Treatment driving individual associations.

To have the misgiving without obstacles Chemotherapy Induced Peripheral Neuropathy Treatment stance and a probability for the market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

About Us Market and Research are a trusted brand in the research industry with the capability of commissioning complex projects within a short span of time with a high level of accuracy. At Market and Research, we believe in building long term relations with our clients. Our services cover a broad spectrum of industries including Energy, Chemicals and Materials, Automotive and Aerospace.

Contact Us: Market and Research United States

Read the original here:

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry...

Assessment of the Chemotherapy Induced Peripheral Neuropathy Market

The latest report on the Chemotherapy Induced Peripheral Neuropathy Market published by Persistence Market Research (PMR) is a valuable tool for established and upcoming market players to solidify their presence in Chemotherapy Induced Peripheral Neuropathy Market landscape. Further, by leveraging the real-time and result-driven insights included in the report, readers can formulate effective business strategies to gain an advantage in the competitive nature of the market.

The presented study suggests that the Chemotherapy Induced Peripheral Neuropathy Market is expected to attain a value of ~US$ XX by the end of assessment period and grow at a CAGR of ~XX% during the forecast period, 2019 2029. The underlying trends, growth opportunities, market drivers, and challenges faced by companies in the Chemotherapy Induced Peripheral Neuropathy Market are analyzed in detail.

Exciting Prices for New Customers!!!Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.persistencemarketresearch.co/samples/30209

Vital Information Included in the Report:

The competitive landscape chapter of the report provides valuable insights related to the business prospects of some of the leading companies in the Chemotherapy Induced Peripheral Neuropathy Market. The product portfolio, pricing structure, revenue growth, and footprint analysis of each market players are included in the report.

Important Queries Related to the Chemotherapy Induced Peripheral Neuropathy Market Addressed in the Report

The dynamics of the Chemotherapy Induced Peripheral Neuropathy Market across major geographical regions are included in the report and represented in the study. In addition, to provide a frictionless reading experience the data is depicted using informative graphs and other graphical illustrations.

Get Access To TOC Covering 200+ Topics at https://www.persistencemarketresearch.co/toc/30209

key players and product offerings

Request Customized Report As Per Your Requirements athttps://www.persistencemarketresearch.co/request-customization/30209

What Makes PMR Different?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751E-mail id- Website:

Read more from the original source:

Chemotherapy Induced Peripheral Neuropathy Market to Witness a Sluggish Growth Owing to Stringent Government Policies in 2019 - 2029 - Markets Gazette...

Latest market research report On Neuropathy Pain Treatment Market from Ample Market Research covers market overview- defines characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for the Neuropathy Pain Treatment industry. The market size section gives the market revenues, covering both the historic data of the market and forecasting the future. Drivers and restraints are studied with respect to external factors influencing the growth of the market. Industry segmentations breaks down the key sub-sectors which make up the market. Additionally, the report also highlights market entry strategies for various companies across the globe. Some of the key players operating in this market include Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals.

Get a complete & Professional sample PDF of the Neuropathy Pain Treatment market report at https://www.amplemarketreports.com/sample-request/global-neuropathy-pain-treatment-market-1248476.html

The report provides insightful and comprehensive information in consideration of the different industry pioneers, including their revenue details, technological advancements, innovations, key developments, SWOT analysis, mergers & applications, future strategies, and market footprint. On the basis of segmentation, the market has been classified into product type, the technologies used, end-user, industry vertical, and geography.

Key companies profiled in this report are Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals and more. These companies are profiled in terms of company basic details, business overview, product knowledge, historical revenue, and recent developments.

The report offers thorough information about the overview and the scope of the Neuropathy Pain Treatment market along with its drivers, restraints, and trends. It also classifies the market into different segments such as by type, by applications and by-product

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into Calcium channel alpha 2-delta ligands, Serotonin-norepinephrine reuptake inhibitors, Others.

In terms of region, this research report covers almost all the major regions across the globe such as Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Oceania], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]

Split by application, this report focuses on consumption, market share and growth rate of Neuropathy Pain Treatment in each application.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.amplemarketreports.com/report/global-neuropathy-pain-treatment-market-1248476.html

The study objectives are:

To analyze and research the Neuropathy Pain Treatment market status and future forecast? involving, production, revenue, consumption, historical and forecast.

To present the key manufacturers, production, revenue, market share, and development plans in the next few years.

To segment the breakdown data by regions, type, manufacturers, and applications of Neuropathy Pain Treatment market.

To analyze the global keyword market opportunity, drivers, challenge, and restraints.

To identify significant trends, influence factors of Neuropathy Pain Treatment market.

To evaluate each submarket with respect to individual growth trends and their contribution to the market.

To examine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

This report can be customized to meet your requirements. Please connect with our sales team who will ensure that you get a report that suits your needs.

https://www.amplemarketreports.com/enquiry-before-buy/global-neuropathy-pain-treatment-market-1248476.html

Lastly, the Neuropathy Pain Treatment Market study provides essential information about the major challenges that are going to influence market growth. The report additionally provides overall details about the business opportunities to key stakeholders to expand their business and capture revenues in the precise verticals. The report will help the existing or upcoming companies in this market to examine the various aspects of this domain before investing or expanding their business in the Neuropathy Pain Treatment market.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

Website: http://www.amplemarketreports.com

Read the original here:

Neuropathy Pain Treatment Market 2019 Share, Growth, Region Wise Analysis of Top Players, Application, Driver, Existing Trends and Forecasts 2026 -...

New medicines and treatments can often help patients better tolerate the sometimes harsh side effects of chemo

Chemotherapy, or chemical treatment, is often recommended as a treatment for a variety of cancers as it uses powerful chemicals to kill fast-growing cells, such as cancer cells, in ones body. Particularly for cancer that has spread to different parts of the body beyond the original tumor, chemotherapy can be effective as it can work throughout the whole body. According to the American Cancer Society, the three main goals for using chemotherapy in cancer treatment are to cure cancer, to control the disease if a cure isnt possible and palliation, to ease symptoms.

Dr. Lindsey Prochaska, DO, a medical oncologist with NHRMC Physician Group - Cape Fear Cancer Specialists, and Katie Evans, an oncology clinical pharmacist at NHRMC, have shared some information about this common cancer-fighting treatment, often called chemo. Prochaska treats patients at Cape Fear Cancer Specialists office in Leland and at New Hanover Regional Medical Centers Zimmer Cancer Center, and Evans collaborates with the oncology teams and patients at the Zimmer Cancer Center.

1) Chemotherapy can be used alone or along with other treatments

Sometimes chemotherapy is the only treatment a patient may need to treat a cancer, other times it may be used along with other forms of treatment.

"Chemotherapy can be used after surgery, before surgery, or even in the metastatic non-curable setting for control of cancer, said Prochaska. In the setting in which surgery removes a cancer, chemotherapy is often used before or after the surgery to rid the bloodstream of cells to reduce recurrence.

Some cancers respond to chemotherapy better than others, and Prochaska said chemotherapy may not be recommended in some circumstances.

More aggressive cancers sometimes respond better to chemotherapy than slow growing ones, she said. Very few cancers have no role for chemotherapy, but if a cancer is caught at a very early stage chemo may not be recommended.

As for if chemotherapy can sometimes provide a complete cure, Prochaska said, Absolutely. When given before or after surgery cure is commonly the goal, she said.

2) Chemotherapy drugs can be taken orally or received through ones veins

Chemotherapy is most often administered intravenously (IV), although, there are some oral chemotherapy treatment options, Evans said. Chemotherapy is administered by chemotherapy certified nurses in the infusion center, whereas, the oral options patients can self-administer following safety precautions for hazardous medications.

3) Chemotherapy can also treat other conditions

Chemotherapy is mostly only used for cancer, but there are some targeted therapies and conventional chemotherapies that treat autoimmune diseases, like lupus and rheumatoid arthritis, Prochaska said.

4) Chemotherapy can reduce chances of a cancer returning

The side effects of chemo can be harsh, but many times when recommended, its to increase the chances of cure, Prochaska said. Chemo can reduce the chances of recurrence 25-50% -- sometimes higher.

5) Side effects are common with chemotherapy

It is true that most systemic chemotherapy can affect both healthy and cancer cells in causing cell death, Evans said. Chemotherapy targets fast growing cells inside of the body which can be both cancer cells and healthy cells. Herein lies the potential for side effects. With newer, more targeted therapy and immunotherapy coming into use, we have seen the potential for side effects to lessen as compared to traditional, systemic chemotherapy.

Evans said these targeted therapies still have side effects that are manageable by an oncologist.

As clinical oncology pharmacists we counsel patients on the side effects they may experience, timeline, and management of the particular side effects with the chemotherapy regimen, she said.

Evans said some common side effects of chemotherapy include lowering blood counts, nausea, vomiting, gastrointestinal disturbances, peripheral neuropathy, hair loss, appetite and taste changes.

Side effects from chemotherapy are common, but can be managed with supportive care medications, Evans said. Once chemotherapy is completed, many side effects will resolve, though we know that some side effects like hair loss and neuropathy will take months to resolve.

Evans said side effects with chemotherapy treatment also differ in the time of onset. The effects on blood cell counts are relatively soon after chemotherapy has begun, hair loss is usually between 2-3 weeks after chemotherapy, and neuropathy may take several weeks before noticing.

Contrary to what some may think, Evans said not all types of chemotherapy cause hair loss.

Prochaska said medications have made a difference regarding some side effects.

Chemotherapy premedications and postmeds have come a long way, Prochaska said. Many people tolerate chemotherapy much better than expected now that we have medications that can help control nausea and vomiting.

Contact the newsroom at 910-343-2384 or Breakingnews@StarNewsOnline.com.

The rest is here:

Health watch: 5 things to know about chemotherapy - StarNewsOnline.com

The research report Neuropathy Pain Treatment Market Global Industry Analysis 2019 2025 offers precise analytical information about the Neuropathy Pain Treatment market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Neuropathy Pain Treatment Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Neuropathy Pain Treatment industry.

This Neuropathy Pain Treatment market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Neuropathy Pain Treatment market research report top-notch.

Interesting? Apply for a sample report: http://www.marketresearchstore.com/report/global-neuropathy-pain-treatment-market-2018-by-manufacturers-353817#RequestSample 

Competitive Landscape

Global Neuropathy Pain Treatment market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Market Segmentation

Neuropathy Pain Treatment Market report segmentation on Major Product Type:Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Others

Market by Application: Here, various application segments of the global Neuropathy Pain Treatment market are taken into account for the research study.

Retail Pharmacies, Hospitals, Others

Enquire Here For Queries Or Report Customization: http://www.marketresearchstore.com/report/global-neuropathy-pain-treatment-market-2018-by-manufacturers-353817#InquiryForBuying

Regional Analysis

The Neuropathy Pain Treatment market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Neuropathy Pain Treatment Market Report:-

What will the market growth rate, overview, and analysis by type of global Neuropathy Pain Treatment Market in 2026?

What are the key factors driving, analysis by applications and countries Global Neuropathy Pain Treatment Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Neuropathy Pain Treatment Market?

Who are the opportunities, risk and driving forces of the global Neuropathy Pain Treatment Market?

Who are the opportunities and threats faced by the vendors in the Global Neuropathy Pain Treatment Market?

What are the Global Neuropathy Pain Treatment market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

More:

Global Neuropathy Pain Treatment Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - World Industry Reports

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris; Seattle Genetics/Takeda) and nivolumab (Opdivo; BristolMyers Squibb) in frontline Hodgkin lymphoma patients aged 60 years and older and in relapsed or refractory classical Hodgkin lymphoma were presented at the 61st annual meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Florida.

According to the American Cancer Society, approximately 8,110 cases of Hodgkin lymphoma will be diagnosed in the United States during 2019 and 1,000 will die from the disease. Approximately half of all newly diagnosed Hodgkin lymphoma patients have Stage III/IV disease. According to the Lymphoma Coalition, over 62,000 people worldwide are diagnosed with Hodgkin lymphoma each year and approximately 25,000 people die each year from this cancer.

Antibody-drug conjugateBrentuximab vedotin is an antibody-drug conjugate or ADC directed to CD30, a defining marker of classical Hodgkin lymphoma. The drug includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Antibody-drug Conjugates are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

With five approved drugs on the market, ADCs have become a powerful class of therapeutic agents in oncology and hematology.

Continued evaluationWe continue to evaluate brentuximab vedotin in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need, said Roger Dansey, MD, Chief Medical Officer at Seattle Genetics.

The data presentations at the annual meeting reinforces our strong commitment to the brentuximab vedotin clinical development program, potentially moving into new patient populations and novel combination treatment strategies, Dansey added.

Frontline therapyData were presented from an updated analysis from the phase II clinical trial evaluating brentuximab vedotin in combination with nivolumab as frontline therapy for Hodgkin lymphoma patients aged 60 years and older. Data were reported from 21 patients, and the median age was 72 years. The majority of patients (76%) had stage III/IV disease at the time of diagnosis.

These results were highlighted in an oral presentation by Christopher A. Yasenchak, MD, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Oregon. [1]

The trial included 19 response-evaluable patients, 18 patients (95%) had an objective response, including 13 patients (68%) with a complete response and five patients (26%) with a partial response.

All response-evaluable patients experienced tumor reduction (complete response + partial response + stable disease) following treatment with brentuximab vedotin in combination with nivolumab. Median duration of response was not yet reached and the maximum duration of response was 22 months and ongoing (95% CI: 7.06, -).

The most common treatment-related adverse events of any grade occurring in at least 20% of patients were fatigue, diarrhea, pyrexia, infusion related reaction, peripheral motor neuropathy, peripheral sensory neuropathy and increase in lipase.

One treatment-related serious adverse event was pyrexia. Fifty-seven percent of patients (12/21) had at least one treatment-related adverse event greater than or equal to Grade 3, most commonly increase in lipase (24%, 5/21), peripheral motor neuropathy and peripheral sensory neuropathy (each 14%, 3/21), and fatigue and hyponatremia (each 10%, 2/21).

These data suggest that brentuximab vedotin + nivolumab is an active treatment with an encouraging CR rate (72%) and appears well tolerated. The results also suggest that with further follow-up and validation, treatment with brentuximab vedotin + Nivo may improve patient outcomes.

Relapsed or Refractory Hodgkin LymphomaA second presentation reported data from 93 patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy who received the combination regimen of brentuximab vedotin plus nivolumab.

After completion of the fourth cycle of treatment, patients were eligible to undergo an autologous stem cell transplant (ASCT). The median age of patients was 34 years.

These results were highlighted in an oral presentation by Alison J. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY. [2]

The study results of this trial showed that of the 91 treated patients, 85% (77/91) had an objective response, including 67% (61/91) with a complete response, 16 patients with a partial response and six patients had stable disease.

From the ninety-one treated patients, sixty-seven patients received an ASCT per trial protocol with no additional salvage therapy. For all treated patients, the two-year progression-free survival (PFS) was 79% (95% CI: 68%, 87%). For the 67 patients who received an ASCT per trial protocol, the two-year PFS was 92% (95% CI: 80%, 97%). Median follow-up for all treated patients was 24.2 months (range 1.8-41.7) and the median PFS was not reached. Estimated overall survival at two years was 94% (95% CI: 85%, 97%) and median overall survival was not yet reached.

Peripheral immune signatures were consistent with an activated T-cell response. Prior to ASCT, the most common adverse events of any grade occurring in more than 20% of patients were nausea, infusion related reaction, fatigue, diarrhea, pruritus, headache, vomiting and pyrexia. Other adverse events included peripheral neuropathy in 16 patients (18%) and neutropenia in six patients (7%). Two patients (2%) discontinued treatment due to adverse events, Grade 3 peripheral neuropathy and increased gamma-glutamyltransferase. Serious adverse events occurred in 14 patients (15%), including pneumonia, pneumonitis and pyrexia (two patients each); and Grade 3 Guillain-Barre syndrome (one patient).

Reference[1] Yasenchak CA, Bordoni R, Yazbeck V, Patel-Donnelly D, Anderson T, Larson T, Newhook T, Mei M, et al. Phase II Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged 60 Years. 61st annual meeting of the American Society of Hematology (ASH). Program: Oral and Poster Abstracts. Type: Oral. Abstract 237. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma Hematology Disease Topics & Pathways: Diseases, Biological, antibodies, Therapies, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies.[Abstract][2] Moskowitz AJ, Advani R, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, et al. Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase I/II Study. 61st annual meeting of the American Society of Hematology (ASH).Program: Oral and Poster AbstractsType: Oral Abstract 238. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma. Hematology Disease Topics & Pathways:Diseases, Biological, Therapies, Hodgkin Lymphoma, checkpoint inhibitors, immunotherapy, Lymphoid Malignancies. [Abstract]

Read more here:

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma - OncoZine

Cancer is a disease caused by unhealthy cells inside the body growing out of control. Lung cancer is the uncontrolled growth of abnormal cells that start off in one or both lungs.

In the United States, is the form of . It is also the most common cause of cancer death in the U.S.

Contents of this article:

Lung cancer can cause a number of complications in the lungs and in other parts of the body. Here are some of the most common complications:

Some of the more common lung cancer symptoms are caused by complications in the lungs.

According to , these complications can lead to the following symptoms:

Pneumonia is a possible symptom of complications in the lungs caused by cancer.

is numbness and tingling feelings in the hands and feet due to damaged nerve tissue. It can be a .

Neuropathy is caused by tumors that grow near the nerves in the arm or shoulder. A compresses the nerves leading to pain and weakness.

This is the in the membrane that covers the lungs. The fluid can then press against the lungs causing breathlessness.

Lung cancers can sometimes affect the heart when they develop near it or close to major blood vessels. This can cause fluid to press against the heart, which may lead to a number of issues.

These issues include:

Depending on its location, a tumor may block a persons airways or food pipe.

A tumor may grow into an airway in the lung and block it. This may lead to other issues, such as pneumonia or shortness of breath.

Lung cancers that grow near a persons food pipe can cause complications, making it difficult for the person to swallow.

Cancers near a foodpipe may lead to a person feeling pain when food passes through to their stomach.

Another serious complication of lung cancer is that it may spread to other parts of the body. Some lung cancer cells can travel through the lymphatic system or through the bloodstream.

If this happens, the cells can become lodged somewhere else in the body. Cancerous cells can then grow in these new locations, causing further cancers.

According to , lung cancer is most likely to spread to:

There are a number of ways to treat all of these different complications. The choice of treatment will vary depending on a number of factors, which include the type of complication, the age, and the general health of the patient.

Here are different treatments for the variety of complications listed above:

Numbness and tingling in the hands or feet may be treated with medication.

Neuropathy as a complication of lung cancer can lead to discomfort. There are many ways to treat the symptoms of neuropathy, including:

Pleural effusion can be treated by slowly draining away the fluid. In order to do this, a tube is inserted into the chest through a small cut.

A person may spend a few days in hospital after this treatment. If the fluid builds up again, they may need to have it drained a further time.

A person with pleural effusion may also have one of the following procedures:

Heart complications can occur if fluid presses against blood vessels because of a tumor. This can be treated in the following ways:

There are a number of procedures to treat lung cancer if it blocks a persons airways. These include the following:

Complications caused by lung cancer can occur over time. They tend to appear as the disease develops.

If a persons lung cancer is detected early, then they have a much higher chance of surviving the disease. Its important for a person to understand the symptoms so that they can get an early diagnosis.

Unfortunately, most cases of lung cancer are diagnosed in the later stages. This is because many of the symptoms or complications of the disease tend not to occur until the cancer is advanced.

Therefore, the individual outlook depends on a number of factors including the type of cancer, how far it has developed, and the persons age and general health.

Written by Adam Rowden

Follow this link:

Medical News Today: Lung cancer complications: Signs, treatment, and outlook - Stock Daily Dish

Pain under the left armpit can be concerning, and many people associate any pain on the left side of their body with a heart attack. However, most of the time, pain under the left armpit has a less serious cause.

The armpit is a complex meeting point for muscles and connective tissues, lymph nodes, and blood vessels. As such, many issues in this area can lead to pain.

Causes range from pulled muscles and mild allergic reactions to more severe issues, such as an underlying infection.

While many of the causes of left armpit pain are not harmful in the long term, anyone experiencing breathing difficulties and pain in their chest, jaw, or neck should see a doctor immediately.

Causes of left armpit pain include:

Many muscles around the shoulder and armpit can cause pain if a person injures them.

People can pull a muscle when reaching for an object, twisting incorrectly, or overstretching.

People who exercise regularly, especially those who do weight training, may be more likely to experience muscle pulls and strains.

In these cases, the pain should go away over time, as long as the individual rests the injured muscle and does gentle stretches.

If the pain does not go away after about a week, it is best to see a doctor.

Armpits are a frequent location for allergic reactions, which could cause pain under the left armpit or both armpits.

Most allergic reactions in this area will occur due to chemicals people apply to their bodies or clothes that touch the armpits.

Possible allergens include:

These products may contain chemicals or perfumes that irritate the skin. A rash may also form.

Anyone who suspects that their skin is sensitive to a particular allergen should note the products they used that day and report them to a dermatologist.

Allergy testing may help find the irritating product. Avoiding products with any harsh chemicals or other ingredients can also improve symptoms in these cases.

Simple cosmetic procedures, such as shaving or waxing, can also be to blame for pain under the armpit. These hair removal techniques may lead to other issues, such as ingrown hairs, cysts, or general irritation and chafing in the armpit.

A skin infection under the armpit may cause itching and pain. Bacteria thrive in warm, damp environments such as the armpits.

An overgrowth of bacteria in this area may lead to an infection, which could cause redness, swelling, and pain, among other symptoms.

Other forms of infection, such as fungal infections due to ringworm or yeast, may also cause similar pain and irritation in the area.

Mild skin infections should clear up without treatment if a person keeps the area clean and dry. However, a doctor may recommend antibiotic creams or medications to treat more severe cases.

Hidradenitis is a chronic condition that causes similar symptoms to severe acne. Hidradenitis occurs due to clogged hair follicles and glands. It is common in areas such as the armpits, where the skin rubs together.

Hidradenitis can lead to multiple cysts or boils developing in the area. In addition to these breakouts, the person will likely experience pain and tenderness.

Doctors can treat hidradenitis with anti-inflammatory medications. Some cases may require surgery.

The varicella zoster virus causes chickenpox and shingles. Breakouts of both illnesses are possible under the armpits, although chickenpox usually begins on the face, back, and chest.

A shingles rash usually develops as a single strip on one side of the face or body, left or right. A person with shingles may also experience:

A person may feel pain and tingling in the area before the visible rash develops.

A doctor may prescribe antiviral medications to speed up the healing process, as well as pain medications to help ease symptoms.

Lymph nodes are small, bean shaped bundles of tissue that play a vital role in the immune system. Lymph nodes help filter toxins from the lymph and deliver white blood cells to help fight disease.

The armpit houses a large number of lymph nodes. Lymph nodes swell as part of an overall reaction by the immune system, such as to an infection or illness.

Swollen lymph nodes in the armpit may cause:

If the swelling does not go down after an infection, such as the common cold, goes away, or the person is not feeling any other symptoms, they should speak to a doctor.

Psoriasis is an autoimmune condition that leads to an overgrowth of skin cells. The buildup of skin cells forms patches called plaques. These plaques can cause symptoms such as itching and pain.

Psoriasis plaques can form anywhere, including the armpit. Some forms of psoriasis are more common in this area, including inverse psoriasis.

Psoriasis treatment typically includes both topical and oral medications to control symptoms.

Nerve damage may also cause pain under the armpit. Nerve damage can be the result of a physical injury, such as one from overuse during sports or from an accident or fall.

Nerve damage can feel like:

Certain conditions, such as diabetes, may also lead to nerve damage or neuropathy. The National Institute of Diabetes and Digestive and Kidney Diseases note that up to half of people with diabetes have peripheral neuropathy, which is nerve damage.

While peripheral neuropathy typically affects the feet and legs, it may also affect the arms in some individuals. Diabetes treatment may help slow nerve damage progression.

Angina occurs due to a lack of oxygen-rich blood flow to the heart. This can be because one of the arteries leading to the heart is narrow or blocked.

Angina causes chest pain and discomfort, which is sometimes severe. It may also cause pressure and pain in other areas, including the:

Some people may also experience a feeling similar to indigestion.

Angina is a symptom of an underlying heart condition, for example, coronary heart disease, which can lead to a heart attack.

There are also many other types of angina. Anyone who suspects they have angina should talk to their doctor.

In rare cases, pain under the left armpit that does not go away may be a sign of a cancerous growth, including breast cancer.

Cancer can cause the lymph nodes under the armpit to swell painfully. An individual may notice a lump under their arm or in their armpit that causes persistent pain or discomfort.

Underarm pain may also be the result of a specific cancer treatment, such as lymph node removal or mastectomy.

Anyone noticing texture changes or lumps in their chest or breast tissue should seek medical attention.

Treatment options for cancer will depend on its stage, which refers to how much it has spread. In general, earlier stages are easier to treat.

Anyone noticing the following symptoms along with left armpit pain should seek immediate medical attention:

A doctor can also diagnose and treat pain from other issues, such as infections or swollen lymph nodes.

Pain under the left armpit from sources such as a pulled muscle should go away within about a week in most cases. Anyone who experiences symptoms beyond this time frame should see a doctor for a full diagnosis.

There are many possible causes of pain under the left armpit. The person may have pulled a muscle or may have swollen lymph nodes from an infection.

Other causes can be more serious, such as angina. Anyone concerned about their symptoms should see a doctor for a full diagnosis and treatment.

Originally posted here:

Pain under left armpit: Causes and what to do - Medical News Today

Results of a recent study suggest a possible role for tumor necrosis factor- (TNF-) in the development of peripheral neuropathy (PN) in patients with multiple myeloma (MM) treated with bortezomib. The studys results were published in the Annals of Hematology.

Inthis study, patients with MM (N=35) were given a maximum of 8 cycles ofbortezomib in addition to dexamethasone. Patients underwent tests of nervefunction, and their serum levels of TNF- were also measured. This study alsoincluded an analysis of the effects of an anti-TNF- monoclonal antibodytherapy in Wistar rats (N=36) that received bortezomib.

Evaluablepatients were stratified based on the cumulative dosages of bortezomib theyreceived. A total of 16 patients (48.5%) had cumulative dosages of less than 39mg/m2, and 17 (51.5%) each received 39 mg/m2 or more of bortezomib.

Amongpatients who received lower cumulative dosages of bortezomib, 43.8% (n=7)experienced PN, compared with an incidence of PN of 82.4% (n=14) among patientswho received 39 mg/m2 or more of bortezomib (P <.05).Grade 3 PN was reported for 2 patients in the higher-dose group.

Baselineserum TNF- levels did not significantly differ between patients whoexperienced PN and those who did not. With bortezomib treatment, TNF- levelsrose overall, but increases were most significant among patients who developedPN of grades 2 to 3. The investigators also reported that most patients withTNF- levels higher than 65 pg/mL had neuropathy symptoms.

Inthe rat model, poorer nerve conduction velocity and evidence of mechanicalallodynia appeared to be associated with bortezomib therapy. Among rats treatedwith bortezomib, however, treatment with the anti-TNF- monoclonal antibody wasassociated with less neurological dysfunction.

Developmentof new neuroprotective agents against TNF- may be a promising therapeuticstrategy to prevent the development of neuropathy, wrote the studyinvestigators in their report.

Reference

Zhao W, Wang W, Li X, et al. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-. Ann Hematol. doi: 10.1007/s00277-019-03816-6

Read more from the original source:

Potential Link Between Tumor Necrosis Factor- and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma - Oncology Nurse...

Thediabetic neuropathy markethas witnessed growth from relentless efforts of various healthcare proponents in expanding the array of various therapies and first line drugs in treating the underlying pain. Players have been able to meet the patient needs because of expanding understanding of physiopathology that promote neuropathic pain in diabetes. Most first line drug therapies notably focus on mitigating toxic effects of hyperglycemia. Several players in the diabetic neuropathy market have been benefitting from the introduction of guidelines that help develop therapies that can optimize pain.

The competitive landscape of the diabetic neuropathy market is characterized by fair degree of fragmentation. A handful of players hold sizable shares in the market. Top names in the diabetic neuropathy market are Janssen Pharmaceuticals, Eli Lilly and Company, Cephalon, NeuroMertrix, and Johnson and Johnson. One of the key strategies they increasingly adopt to consolidate their shares is mergers and acquisitions.

During 2017 2025, the global diabetic neuropathy market is expected to clock a CAGR of 5.4%. By the end of this period, the worth of the global market is anticipated to be US$5.718 bn.

Request a PDF Sample of Diabetic Neuropathy MarketReport

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2199

Prevalence and Complexity Of Diabetic Peripheral Neuropathy Represents Unmet Need

Of the various disorder types, diabetic peripheral neuropathy has attracted the attention of pharmaceutical and biotech companies. By 2025-end, the segment is expected to account for a major share in the global diabetic neuropathy market. The complexity of the type has attracted vast attention of the healthcare industries around the world. The marked prevalence of diabetic peripheral neuropathy adds to its disabling nature. The higher mortality and morbidity of distal symmetrical polyneuropathy is also propelling investments in this area in the global diabetic neuropathy market.

In developed nations, the prevalence of diabetes is increasing at rapid pace. According to recently disclosed statistics by International Diabetes Federation, by 2045 629 million people will be living with diabetes, and currently account for more than 12% of the total spending by adult populations. One of the most complication is diabetic neuropathy. Hence, the condition has attracted groundswell of interest in these nations, such as in the U.S. and the U.K. Further, in recent years, a fast emerging category that is attracting attention of companies in the diabetic neuropathy market is treatment-induced neuropathy in diabetes. Constant advances in understanding of the underlying pathogenesis of diabetic peripheral neuropathy over the last decade have expanded the prospects of the diabetic neuropathy market.

Request for a Discount on Diabetic Neuropathy Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2199

Asia Pacific Fast Emerging as Key Diabetic Neuropathy Market

In the light of developed markets, North America and Europe have emerged as prominent regional markets. A shared factor underpinning the evolution of both these markets are expanding interest in pathophysiological mechanisms. On the other hand, Asia Pacific is emerging as a vastly lucrative region in the global diabetic neuropathy market. This is attributed to the substantial clinical developments in understanding diabetic complications.

Expanding Pharmacological Classes of Drugs Provides New Revenue Base

Lifesciences companies in the global diabetic neuropathy market find it worthwhile and necessary to develop therapies that can target multiple metabolic pathways. Key of these are hyperglycemia, toxic adiposity, mitochondrial dysfunction, and polyol pathway. Promising candidates to emerge in recent years are accumulation of advanced glycation end products (AGEs). Growing research on improving the clinical efficacy of antidepressants and anticonvulsants will likely expand the outlook of the global diabetic neuropathy market.

Of note, developed as developed markets are seeing expanding research in pharmacological classes of drugs. The development of these drugs is fueled by the adoption of multimodal and multidisciplinary approaches. Further, growing focus on developing second or third line treatment is also unlocking new potential in the diabetic neuropathy market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comBlog:https://theglobalhealthnews.com/

Read this article:

Diabetic Neuropathy Market: Technological Growth Map over Time to Understand the Industry Growth Rate - Montana Ledger

Damage to the nerves that control the regulation of involuntary function due to high levels of blood glucose may cause a condition called autonomic neuropathy. An example of body functions such as heart rate, digestion, blood pressure, sexual activity, and perspiration. Cardiac autonomic neuropathy occurs when the heart is affected by nerve damage. Diabetes mellitus patient commonly suffers from cardiac autonomic neuropathy. More than 26 million people in the Unites States get affected by diabetes mellitus. With the increase in age and duration of diabetes mellitus, a prevalence rate of cardiac autonomic neuropathy increase. Cardiac Autonomic Neuropathy is the reason for several cardiac dysfunctions and many medical symptoms which include exercise intolerance, silent ischemia, postural hypotension, resting tachycardia, perioperative instability, and cardiomyopathy.

To Remain Ahead Of Your Competitors, Request for a Sample Here @https://www.persistencemarketresearch.com/samples/14518

Cardiac Autonomic Neuropathy treatment market involves aggressively treating cardiovascular risk factors like hypertension. Cardiac autonomicdeficiency of essential fatty acids, increased oxidative stress, autoimmune damage, and formation of advanced glycosylation end products. Other therapies include in Cardiac autonomic neuropathy treatment include Aldose reductase inhibitor and angiotensin receptor blocker.

Cardiac Autonomic Neuropathy Treatment Market: Drivers and Restraints

In diabetic patients, Cardiac Autonomic Neuropathy characterizes one of the main causes of morbidity and mortality as well as is responsible for cardiac arrhythmias and sudden death which is increasing the demand for cardiac autonomic neuropathy treatment market. Increase in aging population as the well societal influence and changing lifestyles are also the cause of increasing Cardiac autonomic neuropathy treatment market in the world. According to WHO report, more than 23 million people in the United States and an estimated 250 million worldwide are affected by diabetes mellitus. In diabetic patient Cardiac autonomic neuropathy is very common and leads to abnormalities in heart flow rate as well as vascular and peripheral dynamics and reduced quality of life are the drivers for Cardiac autonomic neuropathy treatment market. Some of the Cardiac autonomic neuropathy therapies has shown promising initial result but yet to be validated as well Cardiac autonomic neuropathy treatment management depends on aggressive strategies due to the absence of direct treatment could be the possible restraint for the Cardiac autonomic neuropathy treatment market. Poor reimbursement policies by government and private players also challenge the Cardiac autonomic neuropathy treatment market.

Cardiac Autonomic Neuropathy Treatment Market: Segmentation

Cardiac autonomic neuropathy treatment market is segmented into treatment type which includes pharmacological agents as well as inhibitors and by distribution channel.

Cardiac Autonomic Neuropathy Treatment Market: Overview

Due to increasing aging population and diabetes mellitus, the global market for Cardiac autonomic neuropathy treatment market is expected to gain pull during the forecast period. It is expected centrally acting Cardiac autonomic neuropathy treatment market segment to hold the dominant share in the global Cardiac autonomic neuropathy treatment market due to increasing number of diabetic patients. Also, the increase in number launches of the new drugs cardiac autonomic neuropathy treatment market is increasing globally. Increasing competition among ading drug firms in the market to develop newer drugs tends to drive the cardiac autonomic neuropathy treatment market towards the growth rate.

Cardiac Autonomic Neuropathy Treatment Market: Region-wise Outlook

Based on geographic region, the Cardiac autonomic neuropathy treatment market is segmented into seven significant regions:

North America, Latin America, Europe, Asia-pacific, and Middle East & Africa.

North America is the largest in Cardiac autonomic neuropathy treatment market, owing to high number of diabetes mellitus patient and awareness among patients regarding the harmful effects orpulation as well as growing healthcare expenditure is the reason for significant revenue generation from this region in Cardiac autonomic neuropathy treatment market. Europe is the second largest in Cardiac autonomic neuropathy market due to advancement in technologies and change in lifestyles.

Asia-Pacific is expected to grow at faster rate in the upcoming period due to the increase in the prevalence of diabetes mellitus thus boosting the Cardiac autonomic neuropathy treatment market growth.

Make An Inquiry To Customize This Report @https://www.persistencemarketresearch.com/request-customization/14518

Cardiac Autonomic Neuropathy Treatment Market: Key Market Participants

Some of the key players in Cardiac autonomic neuropathy treatment market are

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Read more:

Cardiac Autonomic Neuropathy Treatment Market by Size | Growth | Analysis | Trends and Forecasts to 2017 2025 - chronicles24

Researchers at Griffith University will undertake a comprehensive assessment of nerve function of people with diabetes to learn more about the onset of peripheral neuropathy.

Neuropathy is the highest reported complication of diabetes worldwide. The most common form of neuropathy is distal symmetrical neuropathy. It causes significant suffering, including loss of sensation in the feet and eventually in the hands.

Around 1.7 million Australians have diabetes, according to Diabetes Australia, and around half of those people could be expected to develop some type of neuropathy. The number of people with diabetes has experienced a fourfold increase, from 108 million adults worldwide in 1980 to 422 million in 2014.

Although diabetic neuropathies are common, surprisingly little is known about the condition and its onset, which is why Eva Sierra Silvestre is leading the DIANE (Diabetic neuropathies) research project, which will assess the function, structure and mechanics of the nervous system in people with diabetes.

What we are planning to do is to create a very comprehensive assessment of nerve function in people with diabetes, she said. By doing that, we may be able to predict or be able to improve prevention and management later on.

An issue with this condition and current screening practices is that sometimes the onset can go unnoticed, so the study will aim to find ways to pick up on peripheral neuropathy in its early stages.

Early detection of diabetic complications is crucial for an effective management of the condition, Ms Sierra Silvestre, a PhD candidate at the Menzies Health Institute Queensland, said.

In research, nerve function in the feet has been studied more than in hands. Typically, it is thought that hands are affected in a later stage but the research team thinks that these changes may occur earlier than what we think. As such, the DIANE research project will focus on assessing subjects hands for any sign of nerve damage.

The researchers are looking for people with diabetes, with and without symptoms of peripheral neuropathy, such as numbness or pain.

Participants will be required to attend three sessions, one each at Griffith Universitys Nathan campus, QUT at Kelvin Grove, and QScan at Red Hill.

To learn more about the study, visit the DIANE Diabetic Neuropathies research project website.

Ms Sierra Silvestres study is one of two ongoing into peripheral neuropathies at Griffith University. Dr Brooke Coombes is also looking for study participants as she investigates a new approach to managing exercise for people with the condition.

Read more:

Study to search for early signs of peripheral neuropathy in people with diabetes - Griffith News

Akcea Therapeutics and Ionis Pharmaceuticals announced the launch of a Phase 3 clinical trial evaluating the safety and efficacy of AKCEA-TTR-LRx (ION-682884) for the treatment of adults with familial amyloid polyneuropathy (FAP).

The global, open-label, randomized NEURO-TTRansform trial (NCT04136184) is expected to start in December. It is recruiting approximately 140 participants ages 18 to 82, diagnosed with stage 1 or 2 FAP, at the Ionis Investigative Site in Boston.

AKCEA-TTR-LRx is a second-generation RNA-targeted therapy in development for the treatment of all forms of transthyretin amyloidosis, including the hereditary (hATTR) and wild-type form of the disease (ATTRwt).

It works by preventing the RNA sequence of the TTR gene, which is defective in people with hATTR, from being translated into a protein. This reduces the buildup of abnormal amyloid deposits that accumulate in several tissues, slowly causing damage and eventually giving rise to symptoms associated with FAP or the other form of hATTR, called familial amyloid cardiomyopathy (FAC). Of note, RNA is the molecule that serves as the template for the production of a protein.

AKCEA-TTR-LRx was originally discovered by Ionis through its proprietary LIgand Conjugated Antisense (LICA) technology platform. It is now being co-developed by Ionis and its affiliate, Akcea.

NEURO-TTRansform will compare the effects of AKCEA-TTR-LRxto the placebo arm of a previous Phase 2/3 trial (NCT01737398), also sponsored by Ionis, that investigated the safety and efficacy of Tegsedi(inotersen) in people with FAP, compared with a placebo.

Once enrolled in NEURO-TTRansform, participants will be randomly assigned to receive subcutaneous (under-the-skin) injections of AKCEA-TTR-LRx every four weeks, or Tegsedi once a week. All study participants also will receive daily supplemental doses of the recommended daily allowance of vitamin A.

Those who are initially assigned to Tegsedi (20 out of the 140 expected to enroll), will cross over to AKCEA-TTR-LRx after 35 weeks.

The studys main goals, which will be assessed at 66 weeks, include analyzing changes from the studys start in the levels of TTR found in the serum, as well as changes in the scores of the modified Neuropathy Impairment Score +7 (mNIS+7) and of the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN).

The mNIS+7 is a measure of neurological impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function; the Norfolk QoL-DN evaluates the impact of neuropathy on individuals quality of life.

An interim analysis is planned at 35 weeks to assess changes from the studys start in the levels of TTR found in the serum and in mNIS+7 scores.

Patients enrolled in NEURO-TTRansform will be followed for 85 weeks. After completing the study, they will have the option to enroll in an open-label extension study.

The initiation of the TTRransform Phase 3 program represents an expansion of our dedication and commitment to the ATTR community. The NEURO-TTRansform study is the first of two Phase 3 studies that we expect to initiate with AKCEA-TTR-LRx. Our Phase 1 data are encouraging and we are excited about the possibility of delivering a significant advancement for people living with hATTR amyloidosis, Damien McDevitt, PhD, Akceas interim CEO, said in a press release.

In a previous Phase 1 trial (NCT03728634) sponsored by Ionis, it was shown that monthly 90-mg injections of AKCEA-TTR-LRx could lower the levels of transthyretin (TTR), the protein involved in FAP, by up to 94% after 13 weeks of treatment in a group of healthy volunteers.

The Phase 1 data of AKCEA-TTR-LRx are consistent with the clinical profile seen across our other LICA programs, highlighting the potential of LICA-engineered therapies to address both rare and more common diseases, said Brett P. Monia, PhD, chief operating officer of Ionis.

We remain dedicated to advancing this important clinical development program as rapidly as possible and are hopeful about the prospect of bringing a new safe and effective treatment to people living with the devastating symptoms of hATTR amyloidosis in the years ahead, Monia added.

The company also launched the Phase 3 CARDIO-TTRansform clinical trial (NCT04136171), to test AKCEA-TTR-LRx in people with transthyretinmediated amyloid cardiomyopathy (ATTR CM), or FAC. The trial is not yet enrolling.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 2

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Read this article:

Phase 3 Trial of Investigative FAP Therapy AKCEA-TTR-LRx Launching - FAP News Today

AMA recently published a detailed study of over 180+ pages in its repository on Neuropathy Pain Treatment market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are Pfizer [United States], Depomed [United States], Eli Lilly [United States], Endo [Ireland], Grnenthal Group [Germany], Arbor Pharmaceuticals [United States], Astellas Pharma Inc. [Japan], Biogen Inc. [United States], Baxter Healthcare Corporation [United States], Sanofi S.A [France], Abbott Laboratories [United States], AstraZeneca [United Kingdom], Johnson & Johnson Services Inc. [United States], GlaxoSmithKline plc [United Kingdom], Depomed Inc. [United States].

Neuropathy pain treatment involves cure of pain associated with somatosensory nervous system. As of 2018 data, 18% of Canadian population, 7% of French and over 4% of United Kingdom population experience pain of neuropathic origin. With growing geriatric population across the world, the number of neuropathic pain causing diseases will increase significantly, thus, giving pain treatment services offering companies an opportunity to explore in untapped market.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @ https://www.advancemarketanalytics.com/sample-report/32655-global-neuropathy-pain-treatment-market

Market Segmentation

by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain, Others), Indication Type (Diabetic Neuropathy, Trigeminal Neuralgia, Post-herpetic Neuralgia, Chemotherapy-induced Peripheral Neuropathy, Others.), Treatment (Medication, Multimodal Therapy), Distribution Channels (Pharmacies, Retail Pharmacies, Online Pharmacies), End-user (Hospitals, Clinics, Research Organizations), Diagnosis (Imaging, Blood Tests)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/32655-global-neuropathy-pain-treatment-market

Whats Trending in Market:

Increasing Demand of Generic Drugs

Emergence of Innovative Pain Treatment Methods Such as Use of Electrical Stimulation Devices, Stem Cell Procedures and Others

Growth Drivers: Rising Geriatrics Population Across the World

Growing Number of Cancer and Diabetes Cases

Restraints: High Cost of Neuropathy Pain Treatment

Lack of Health Infrastructure and Budgets in Emerging Countries

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/32655-global-neuropathy-pain-treatment-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Try a limited scope research document specific to Country or Regional matching your objective.

GET FULL COPY OF United States Neuropathy Pain Treatment market study @ USD 2000

And, Europe Neuropathy Pain Treatment market study @ USD 2500

Strategic Points Covered in Table of Content of Global Neuropathy Pain Treatment Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Neuropathy Pain Treatment market

Chapter 2: Exclusive Summary the basic information of the Neuropathy Pain Treatment Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Neuropathy Pain Treatment

Chapter 4: Presenting the Neuropathy Pain Treatment Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Neuropathy Pain Treatment market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=32655

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

[emailprotected]

Ph: +1 (206) 317 1218

Go here to see the original:

Neuropathy Pain Treatment Market Set For Rapid Growth and Trend | Statistics Analysis and Opportunities 2024 - News Description

The Global Neuropathy Pain Treatment Market is the increasing incidence of neuropathic pain caused by damage or

disease affecting the somatosensory nervous system. Growing awareness among patients and increase in the demand for generic drugs boost the market growth. However, severe side effects of opioids and steroids and rising costs of branded drugs might hamper the market growth

Buy one-Get one: https://www.orianresearch.com/checkout/956157

[Buy this report and get another report of the same price for free. offer for limited period only].

Based on type, the market is divided into:

Based on application, the market is divided into:

Moreover, the market is classified based on regions and countries as follows:

For More Info, Get Sample Report Here @ https://www.orianresearch.com/request-sample/956157

Key Market Players:

Key Benefits of the Report:

Target Audience:

GET Flat 40% Discount https://www.orianresearch.com/discount/956157

[Avail flat 40% discount on this report. offer for limited period only]

Table of Contents

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Website: http://www.orianresearch.com

See the original post:

Global Neuropathy Pain Treatment Profiling Industry 2019 Market Share, Regional Analysis, Growth Insights, Leading Companies, End Users and Forecast...

Rising Prevalence of Cancer Worldwide to Promote Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth

A painful dysfunction of the somatosensory nervous system in the body is called chemotherapy-induced peripheral neuropathy or CIPN. It is estimated that chemotherapy-induced peripheral neuropathy affects an estimate of 68.0% patients who undergo within their first month of diagnosis, among which 30% patients are affected on a chronic basis. The rising prevalence of chronic diseases is promoting the growth of Chemotherapy Induced Peripheral Neuropathy Treatment market. According to Fortune Business Insights, the market for Chemotherapy Induced Peripheral Neuropathy Treatment is anticipated to rise exponentially with increasing prevalence of diabetes worldwide.

Browse Complete Report [emailprotected] https://www.fortunebusinessinsights.com/industry-reports/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Rising Prevalence of Cancer to Help Generate High Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenues

The increasing prevalence of chronic diseases such as diabetes and cancer are the major factors promoting the Chemotherapy Induced Peripheral Neuropathy Treatment market. The surge in adoption of chemotherapy is significantly helping to increase the prevalence of peripheral neuropathy. Additionally, lack of proper guidelines about chemotherapy heightens the chance of additional incidence of peripheral neuropathy. This is expected to bode well for generating greater percentages of the global Chemotherapy Induced Peripheral Neuropathy Treatment market share.

However, the market may face certain challenges in terms of the lack of awareness about symptoms of chemotherapy-induced peripheral diagnosis, especially in developing nations. Such challenges may hamper the global Chemotherapy Induced Peripheral Neuropathy Treatment market growth in the forecast period.

Get PDF Brochure of this [emailprotected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Some of the companies operating in the global Chemotherapy Induced Peripheral Neuropathy Treatment market include:

Improving Healthcare Infrastructure and Medical Facilities of Developing Nations to Help Asia Pacific Market Grow Significantly

According to the Center for Diseases Control and Prevention (CDC), ABOUT 1,633,390 new cancer cases were reported in the U.S. in 2015, among which, an estimated 595,919 people died of cancer. As per the geographical categorization, North America is currently holding a significant share in the global Chemotherapy Induced Peripheral Neuropathy Treatment market and is anticipated to continue doing the same in the forecast period as well. This is attributable to the rising prevalence of cancer which is further propelling the demand for chemotherapy treatment by patients and their family members.

On the other side, the global Chemotherapy Induced Peripheral Neuropathy Treatment market in Asia Pacific and Europe will also witness remarkable growth rate during the forecast period owing to improving healthcare infrastructure and medical facilities, especially in the developing nations.

Strategic Partnerships to Help Market Players Gain Strong Foothold in Market

As per the report, the global Chemotherapy Induced Peripheral Neuropathy Treatment market highlights some of the major market shareholders significantly driving the market. These companies are mentioned below

Manufactures continue to focus on new product launches and merger and acquisition strategies to increase their customer base and broaden product portfolio. These manufacturers produce new therapeutic methods to maintain a strong foothold in the market. Some of the recent development made by companies are mentioned below

More Trending Topics From Fortune Business [emailprotected]

U.S. Biosimilars Market 2019 Global Technology, Consumption, Segmentation, Growth, Development, Trends and forecasts to 2026

Mass Spectrometer Market Size Overview by Share, Growth Factor, Industry Trends, and Analysis to 2026

About Us

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune Business Insights

The rest is here:

Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune...

Diabetic Peripheral NeuropathyMarket

Diabetic PeripheralNeuropathy-Epidemiology Forecasting Intelligence report provides acomprehensive analysis of the Diabetic Peripheral Neuropathy epidemiology,providing the historical, current, and forecasted data for the United States,European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) andJapan during the period from 2018-2028.

Our epidemiology services include:

Incidence andprevalence Diagnosis rate, treatment rate and mortality patterns Epidemiology-based forecasting and disease trends Size of different patient segments in a disease area Population based: disease occurrence, co-morbidities and treatment patterns Geographic Regional Ethnic differences

Along with the epidemiological data, the reportalso includes:

Disease overview,causes, symptoms, classification, risk factor, pathophysiology, diagnosis andtreatment Patient treatment journey Treatment algorithm and guidelines Assesses the disease risk and burden Highlights the unmet needs Market driver and barrier Growth opportunities and market trend analysis

Methodology

This report isbuilt using data and information sourced from proprietary databases, primaryand secondary research and in-house Epidemiology Forecast model analysis by ateam of industry experts. To generate accurate patient population estimates, utilizes a combination ofseveral world class sources that deliver the most up to date information frompatient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have beenidentified in the report.

Note:

Systematic review ofthe epidemiological literature is also provided for full transparency intoresearch and methods. This report can be delivered to the clients within 4-5business days.

Request customize:-

If you wish to find more details ofthe report or want a CustomizationPlease contacts us. You can get adetailed of the entire research here.

Ozone Market Reports is committed towards delivering intensiveresearch based analysis reports, enabling clients to easily make fact-baseddecisions. We also have with us the facility of our innovatively designed anddeveloped data processing and analysis division.

Ozone Market Reports is a research-based consulting firmspecializing in getting research inputs and using them appropriately in themarketing planning process. In saying this, we are trying to convey that wealways attempt to interpret the research data from the viewpoint ofrecommending action priorities both short-term and long-term. To this end, wehave put together a team that understands not only research techniques, butalso branding concepts in depth.We believe our people are our clientsbiggest assetshence we do our best to recruit multi-skilled individuals,and then give them an environment where they can think and ideate freely.

We offer various services for our clients to help them choosewhats most relevant and best for them required for their business.

Contact Us:

Name: Steven Samuel

Email info@ozonemarketreports.com

Phone +91 9370882135

Website: https://www.ozonemarketreports.com/

Post Views: 70

Read the original post:

Diabetic Peripheral Neuropathy Market - Growth, Future Prospects, and Competitive Analysis 2028 - Market Tribunal

For patients with diabetes, cardiovascular disease should be a top priority.

Nathan D. Wong, PhD, director of the Heart Disease Prevention Program at the University of California, Irvine, is a co-author of the Heart Disease and Diabetes chapter in the NIDDK publication Diabetes in America, 3rd Edition. Here he talks about the importance of broadening the clinical focus of diabetes care from hemoglobin A1C to also include other risk factors for cardiovascular disease common in patients with diabetes.

Q: Why is it so important to talk about heart disease with patients who have diabetes?

A:More than two-thirds of patients with diabetes will die of cardiovascular-related illnesses such as coronary heart disease, stroke, heart failure, and peripheral arterial disease. For women with diabetes, the risks for different forms of cardiovascular disease are three to seven times greater compared with women who do not have diabetes. For men with diabetes, the risk is two to three times greater.

We are doing a poor job of managing heart disease in people with diabetes in this country and throughout the world, despite many advances in therapies over the past 30 years. We still have a very small percentage of people with diabetesfewer than one in fivewho meet appropriate targets for hemoglobin A1C, blood pressure, and LDL cholesterol; even fewer additionally meet the recommendations for physical activity, a healthy diet, nonsmoking status, and body mass index.

Many of these factors have an impact on risk for certain microvascular complications associated with diabetes such asretinopathy, nephropathy, and neuropathy. But these factors also affect risk for macrovascular complications such as heart disease and stroke.

Q: How does cardiovascular risk differ for type 1 and type 2 diabetes?

A:When people are diagnosed with type 2 diabetes, they often already have hypertension and dyslipidemia. For people with type 1 diabetes, the diagnosis generally comes when theyre much younger, so they arent yet at significant cardiovascular risk. Theres a true opportunity to help prevent them from developing cardiovascular risks in the first place, rather than trying to catch up with these factors after theyve developed and are more difficult to control.

Q: What are the benefits of keeping all the cardiovascular risk factors at target levels?

A: The Steno 2 clinical trial found a 53% risk reduction in cardiovascular outcomes for people with type 2 diabetes who were intensively treated for risk factors, compared with participants in the control group. In a follow-up paper, the researchers reported on mortality rates after 13 years. They found it was significantly lower for the intensively treated group. Just 30% had died, compared with 50% of the conventionally treated group.

In an observational study, we pooled data on people with diabetes from three different clinical trials to show an approximately 60% lower risk for developing coronary heart disease or cardiovascular disease in people with diabetes who were at target levels for LDL cholesterol, blood pressure, and hemoglobin A1C. This suggests we can possibly reduce the risk of future heart attacks or strokes by more than half, if we ensure that these factors are controlled.

Q: What does this mean for diabetes care?

A:We still have a lot of work to do to get the word out that diabetes is really a cardiovascular condition. Most people with diabetes are not dying from retinopathy or neuropathy; they are dying from cardiovascular disease. This is not to trivialize the microvascular complications. Obviously, neuropathy or retinopathy can significantly affect quality of life. But in terms of what a person with diabetes eventually will die of, its cardiovascular disease. Patients and their health care providers really have to better understand that controlling diabetes is much more than controlling blood sugar.

Certainly, managing glucose is critical to prevent microvascular complications, in particular. There is strong epidemiologic data that adverse cardiovascular outcomes are greater in people with higher levels of hemoglobin A1C, but the evidence is less striking for improving cardiovascular outcomes from glucose control alone. And in fact, the ACCORD trialactually showed increased cardiovascular mortality to occur when targets were set too aggressively for hemoglobin A1C.

Q: How can the message on cardiovascular risk factors reach more health care professionals?

A:I think theres tremendous opportunity to advance professional education to help improve cardiovascular outcomes in people with diabetes. And this, of course, can be accomplished with lifestyle changes. But few people with diabetes see a dietician and/or exercise physiologist as frequently as they should to help them with theirdiabetes self-management. These allied health care providers are not traditionally part of the health care team as much as they should be, because reimbursement is not always available for their services. Physicians need to know that these resources exist, and that they can also prescribe lifestyle improvements such as walking or eating more vegetables.

At professional meetings, I've asked for a raise of hands: How many of you physicians have heard of the American Medical Association? Virtually all of them have. Then I ask, How many of you have heard of theAcademy of Nutrition and Dietetics? Very few have, yet this is a very powerful group. Specifically, the Academys Sports, Cardiovascular and Wellness Nutrition dietetic practice group includes close to 10,000 people around the country. The American College of Sports Medicine includes exercise physiologists. But there's a disconnect. We need to help physicians know that these other providers, who are key to patients success in managing their diabetes and cardiovascular risks, exist.

Q: How can cardiologists contribute to better care for patients with diabetes?

A:The American College of Cardiology advocates for cardiologists to learn more about how to manage diabetes. This is largely fueled by the fact that we now have newer medications that are shown to reduce cardiovascular events in people with diabetes. These drugs are not the most powerful A1C-lowering agents, but theyre the only agents shown to have benefits in terms of cardiovascular outcomes. The sodium-glucose cotransporter-2 (SGLT2) inhibitors, in particular, have the dramatic effect of reducing heart failure-related hospital stays by more than 30%. Equally exciting are the glucagon-like peptide-1 (GLP-1) receptor agonists, which seem to have more of an anti-atherosclerotic effect.

Both of these therapies have been incorporated into several guidelines. The American College of Cardiology, the American Association of Clinical Endocrinologists, the American Diabetes Association, and the American Heart Association recommend these therapies specifically for people with pre-existing diabetes and cardiovascular disease.

But its mainly the specialty community that has started to use these therapies. We need to increase efforts to communicate the value and the indications of these therapies among primary care providers, too.

Q: What advice do you have for health care professionals so that they can better help their patients with diabetes manage the cardiovascular risk factors?

A:Providers and patients with diabetes alike need to understand that cardiovascular disease should be their main concern. It takes a concerted approach to manage all the relevant risk factors to significantly improve outcomes. Were talking about a multidisciplinary cardio-diabetes care team that includes lifestyle specialistsdieticians and physical activity expertsas well as other appropriate specialists, including the endocrinologist and the cardiologist, and, in many cases, the primary care provider at the center of the patients care.

Health care professionals also need to motivate patients to take greater charge in their health care.Shared decision-making is very important in starting new therapies and managing lifestyle changes.

What has been your experience addressing cardiovascular risk in your patients with diabetes? Tell us below in the comments.

Follow this link:

Addressing Cardiovascular Risk Factors in People with Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

The Inherited Neuropathy Consortium led by University of Iowa neurologist Michael Shy has received a grant renewal to continue studying inherited neuropathies.

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

Gaoyuan Pan

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

Gaoyuan Pan

Gaoyuan Pan

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

As clinical research of medical technology advances, so will the understanding of genetic neurological diseases. The National Institute of Health has renewed the University of Iowas grant to study inherited neuropathic diseases.

The Inherited Neuropathy Consortium, located in the UI Carver College of Medicine, recently received a five-year $7.2 million grant renewal to continue researching inherited peripheral neuropathies in the hope of finding a cure for related diseases.

Peripheral neuropathies are disorders affecting the nerves that spread from someones back to their hands and feet, which can cause weakness and balance problems, UI neurologist Michael Shy said. Although these disorders have many causes, he said, a common cause is a genetic mutation that can disrupt the nerves.

Shy said the diseases are referred to as Charcot-Marie-Tooth type 1 or type 2, depending on which part of the nerve the disease affects. These diseases are fairly common and affect one in 2,500 people, he added.

Up until 1990, there were no known genetic causes for any of these, although it was known that the diseases could be genetic, Shy said. Now theres mutations in over 100 different genes that can cause these disorders.

The consortium works with other institutions around the world to determine how these diseases change over time, identify other genetic causes of Charcot-Marie-Tooth, and train physicians to study and treat the diseases, Shy said.

With the grant renewal, the consortium will continue its study of how Charcot-Marie-Tooth changes over time through using different outcome measurements they have developed and new instruments allowing them to measure outcomes in infants, Shy said.

RELATED: UI doctors prepare to study obscure leading cause of death in refractory epilepsy

The grant will also allow researchers to continue to identify and study biomarkers in patients blood that are common for Charcot-Marie-Tooth, he said.

Even though clinical trials have been developed to treat the diseases, there is no cure, Shy said. The clinic emphasizes genetic counseling to help people understand their condition and the potential it has to pass on to other generations, he said.

Counselors meet with families to discuss genetic testing options, provide an understanding of what their insurance will cover, and an understanding of the various lab testing they will receive, said Shawna Feely, genetic counselor and clinic coordinator.

Feely is the consortiums project manager and oversees the 20 sites involved. She helps research teams navigate protocols, understand the testing, and create uniformity in the way clinical trials are conducted.

RELATED: University of Iowa receives grant to improve statewide-maternal-health

Any time youre giving a genetic diagnosis, there can be an emotional element to the person or family in terms of family dynamics or feeling guilt that someones passed a genetic disease on, and so genetic counselors part of the counseling part is to help families cope, Feely said.

Genetic counselor Tiffany Grider said in an email to The Daily Iowanthat a common question from patients is whether or not their child will have the same condition, and whether theres a treatment for it.

Researchers like Dr. Shy have spent decades learning the exact biological mechanism for how these diseases happen, Grider said.

With the developing research and the grant, the future of the clinic and genetic testing will be in the hands of the next generation, Shy said.

Its this next generation of scientists who are going to take this to the clinic, so these are going to become treatable diseases, Shy said. And we need that generation to be well-trained to be able to develop [treatments].

Read the original:

UI-led neuropathy consortium receives grant renewal from National Institute of Health - UI The Daily Iowan